Prediction of Erosive Disease Development by Antimitochondrial Antibodies in Rheumatoid Arthritis
Authors' conclusion
AMAs were used to stratify patients based on disease phenotype and to predict development of erosive disease, including in patients with seronegative disease.
Study context
- Population
- Patients with rheumatoid arthritis (RA) from 3 cross-sectional cohorts and a longitudinal inception cohort, and healthy individuals3 RA and 3 healthy cohorts
- Exposure
- RA patients vs healthy individuals; AMA-positive vs AMA-negative RA
- Outcome
- Presence and significance of antimitochondrial antibodies (AMAs) in RA
Methodological details3 cross-sectional cohorts, longitudinal inception cohort (median follow-up 8 years), flow cytometry-based assay
- 3 cross-sectional cohorts
- Longitudinal inception cohort (median follow-up 8 years)
- Flow cytometry-based assay
Main finding
As reported in the abstract
AMA levels, RA vs healthy individuals
| Group | Value | AMA positivity range |
|---|---|---|
| RA | 14-26% | 14-26% |
RA
Value14-26%
AMA positivity range14-26%
- RA vs Healthy individuals: P < 0.001, P < 0.05, and P < 0.01 — elevated in all 3 cohorts
Observational data: associations, not effects.
Further findings
| Outcome | OR | P value |
|---|---|---|
| Anti-MFN-1 antibody levels, RA vs healthy individualsElevated in RA | P < 0.001 | |
| AMA levels predicting erosive disease, independent of ACPAIndependent of ACPA | 4.59 | P = 0.006 |
| AMA levels predicting joint space narrowing, independent of ACPAIndependent of ACPA | 3.08 | P = 0.02 |
| Anti-MFN-1 antibodies identifying seronegative patients developing erosive diseaseSeronegative patients | 9.33 | P = 0.02 |
Anti-MFN-1 antibody levels vs AMA levels (correlation)
- Correlation r
- 0.31
- P
- P = 0.006
Association of AMA presence with erosive disease and ILD
- Erosive disease
- P < 0.05
- ILD
- P < 0.01
Original publication
Prediction of Erosive Disease Development by Antimitochondrial Antibodies in Rheumatoid Arthritis. Arthritis Rheumatol. Published 29 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →